As a Joint Venture CEK were subject to the following contractual clause:<\/p>
<\/p>
Z12 Joint and several liability<\/strong><\/p> Z12.1 If the Contractor<\/em> is a Joint Venture<\/p> (1) each of the parties comprising the Joint Venture are jointly and severally liable to the Employer<\/em> for the performance of this contract and all liabilities, acts and omissions of the Contractor<\/em> under or in connection with this contract are the liabilities, acts or omissions of each party comprising the Joint Venture under or in connection with this contract,<\/p> (2) without limiting or prejudicing any other provisions of this contract, if any of the parties comprising the Joint Venture ceases to be a member of the Joint Venture or suffers one of the events described in clause 91.1, the other parties or party carry out and complete the works<\/em> in accordance with this contract,<\/p> (3) the Contractor<\/em> gives notice to the Employer<\/em> and the Project Manager<\/em> as to which of the parties comprising the Joint Venture has the authority to bind the Contractor<\/em> for all the purposes of this contract and<\/p> (4) the Contractor<\/em> keeps the Employer<\/em> and the Project Manager<\/em> informed promptly of any changes in the Joint Venture whether in relation to any incorporated entity or its constituent entities or the entities forming an unincorporated joint venture, including changes in legal status, the occurrence of any of the events described in clause 91.1, amalgamation, demerger, merger, deterioration in financial condition, de-ratings, major legal claims and suits, and any other matter or circumstance that could reasonably be deemed to be of concern to the Employer<\/em> or the Project Manager<\/em>.<\/p> <\/p> [Regarding (4) above, Carillion Construction Limited was subject to an \u2018event described in clause 91.1\u2019 when it was put into liquidation on 15 January 2018]<\/p> <\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4460", "label" : {"_value" : "Biography information for Ms Nusrat Ghani"}
}
, "answeringMemberConstituency" : {"_value" : "Wealden"}
, "answeringMemberPrinted" : {"_value" : "Ms Nusrat Ghani"}
, "dateOfAnswer" : {"_value" : "2018-02-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-02-28T16:20:46.383Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "27"}
, "answeringDeptShortName" : {"_value" : "Transport"}
, "answeringDeptSortName" : {"_value" : "Transport"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "High Speed Two"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Transport, pursuant to the Answer of 18 January 2018 to Question 122605 will he publish the clauses of the contract between HS2 Ltd and CEK JV for HS2 that guarantee the full delivery of the HS2 contract now that Carillion is unable to fulfil any part of that contract.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129383"}
, {"_about" : "http://data.parliament.uk/resources/847707", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847707/answer", "answerText" : {"_value" : " We recognise that the causes of health inequalities are multi-faceted and highly complex. We take a comprehensive and strategic approach to reducing health inequalities that addresses the root social causes, promotes healthier lifestyles for all and improves the consistency of NHS services.<\/p> <\/p> We have taken tough action to protect the public\u2019s health - introducing a sugar tax as part of our childhood obesity plan, standardised packaging cigarettes and a world-leading diabetes prevention programme. It will take time for these measures to have an effect, so no assessment of their impact has been made. Our commitment is demonstrated by the £16 billion we will invest over the current spending period until 2020 to support local public health services. Local authorities must consider health inequalities when investing this ring-fenced money.<\/p> <\/p> We have introduced transparent measurement through high level measures to reduce health inequalities in life expectancy and healthy life expectancy in the Public Health Outcomes Framework and NHS Outcomes Framework. In March 2015, we published an additional list of selected NHS Outcomes Framework indicators for which health inequalities data has been made available. Last year Public Health England (PHE) published a report entitled \u2018Public Health Outcome Framework: Health Equity Report\u2019, which provides detailed statistics on the distribution and drivers of health inequality across England, with a specific focus on ethnicity. The report is available at:<\/p> <\/p> https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/629563/PHOF_Health_Equity_Report.pdf<\/a><\/p> <\/p> PHE has published a number of statistics, evidence reports and tools to enable local government and the wider public health system to take effective action on health equity.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-02-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-02-28T17:21:29.03Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Life Expectancy"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 22 January 2018 to Question 123454, what assessment he has made of the implications for his Department's policies of the decline in life expectancy in some local authority areas and the disparity in life expectancy across local authorities.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"}
}
, "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"}
, "tablingMemberPrinted" : [{"_value" : "Chris Ruane"}
], "uin" : "129512"}
, {"_about" : "http://data.parliament.uk/resources/847708", "AnsweringBody" : [{"_value" : "Department for Education"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847708/answer", "answerText" : {"_value" : " Schools are responsible for ensuring that all staff, including supply staff, are aware of their safeguarding responsibilities. \u2018Keeping Children Safe in Education\u2019 statutory safeguarding guidance makes clear that all staff should read \u2018Part One - Safeguarding information for all staff at induction\u2019. It also requests that governing bodies/proprietors ensure that mechanisms are in place to support staff to understand and discharge their role and responsibilities as set out in Part One. The guidance states that all staff should receive safeguarding and child protection training at induction.<\/p> <\/p> Before placing a member of staff a supply agency must request sufficient information, including the experience, references, training, and qualifications the school needs for the post or that are required by law.<\/p> <\/p> To help schools achieve best value when using supply agencies the Department is working with the Crown Commercial Service to develop a commercial framework for agency supply teachers. Together with other requirements the framework will ensure that agencies adhere to standard levels of practice. The framework is expected to be available for schools to use from September 2018.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/111", "label" : {"_value" : "Biography information for Nick Gibb"}
}
, "answeringMemberConstituency" : {"_value" : "Bognor Regis and Littlehampton"}
, "answeringMemberPrinted" : {"_value" : "Nick Gibb"}
, "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-05T17:04:09.023Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "60"}
, "answeringDeptShortName" : {"_value" : "Education"}
, "answeringDeptSortName" : {"_value" : "Education"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Supply Teachers: Training"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Education, what assessment he has made of the (a) adequacy and (b) extent of the provision of safeguarding training provided by supply teacher agencies in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/534", "label" : {"_value" : "Biography information for Chris Ruane"}
}
, "tablingMemberConstituency" : {"_value" : "Vale of Clwyd"}
, "tablingMemberPrinted" : [{"_value" : "Chris Ruane"}
], "uin" : "129384"}
, {"_about" : "http://data.parliament.uk/resources/847709", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847709/answer", "answerText" : {"_value" : " We have made no such assessment. Prescribers are able to use medicinal products outside their licensed indications where they are satisfied that they best meet the individual clinical needs of their patient. This is part and parcel of normal clinical practice.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-02-28", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-02-28T17:18:23.013Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mast Cell Activation Syndrome"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of allowing the use of off-label medications in the treatment of Mast Cell Activation Syndrome.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129385"}
, {"_about" : "http://data.parliament.uk/resources/847710", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847710/answer", "answerText" : {"_value" : " NHS England does not have any current plans to assess the coding of National Health Service care for patients with Mast Cell Activation Syndrome.<\/p> <\/p> In response to the commitments outlined in the UK Strategy for Rare Diseases, NHS England published the Rare Diseases Implementation Plan in which it proposed to monitor the development of International Classification of Diseases (ICD)-11 and support the accurate characterisation of patients through Human Phenotype Ontology terms as being developed through the 100,000 Genomes Project.<\/p> <\/p> More information about the NHS England Rare Diseases Implementation Plan can be found here:<\/p> <\/p> https://www.england.nhs.uk/publication/implementation-plan-for-the-uk-strategy-for-rare-diseases/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-05T15:41:57.293Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mast Cell Activation Syndrome"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the accuracy of the coding of diagnoses of Mast Cell Activation Syndrome on NHS systems.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129386"}
, {"_about" : "http://data.parliament.uk/resources/847711", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847711/answer", "answerText" : {"_value" : " Care for patients with Mast Cell Activation Syndrome (MCAS) in an outpatient setting will typically be within local allergy clinics, available in most hospitals. These services are commissioned locally by clinical commissioning groups. There are no current plans to designate or commission the care of patients with MCAS as a prescribed national specialised clinic or service.<\/p> <\/p> A list of local allergy clinics can be obtained from the British Society for Allergy and Clinical Immunology at:<\/p> <\/p> http://www.bsaci.org/professionals/allergy-specialists<\/a><\/p> <\/p> The Royal College of Physician\u2019s Improving Quality in Allergy Services scheme at:<\/p> <\/p> www.rcplondon.ac.uk/projects/outputs/improving-quality-allergy-services<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"}
}
, "answeringMemberConstituency" : {"_value" : "Winchester"}
, "answeringMemberPrinted" : {"_value" : "Steve Brine"}
, "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-05T15:44:46.98Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mast Cell Activation Syndrome"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if his Department will establish a multi-disciplinary centre of excellence with leadership from a senior clinician to focus on Mast Cell Activation Syndrome.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129387"}
, {"_about" : "http://data.parliament.uk/resources/847712", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847712/answer", "answerText" : {"_value" : " Mast Cell Activation Syndrome (MCAS) does not currently have a specific disease category within the 100,000 Genomes Project but patients with MCAS in the context of other medical disorders or congenital malformations suggestive of a genetic cause are eligible. In addition, a proposal for inclusion of familial MCAS in the project is currently under peer review and will be considered by the Genomics England Science Advisory Committee at their next meeting.<\/p> <\/p> Genomics England will seek to establish links between the relevant Genomics England Clinical Interpretation Partnership (GeCIP) domains and the MCAS Research Centre at the University Of Bonn Institute Of Genetics.<\/p> <\/p> More about GeCIP can be found here:<\/p> <\/p> https://www.genomicsengland.co.uk/about-gecip/<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
}
, "answeringMemberConstituency" : {"_value" : "Thurrock"}
, "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
, "dateOfAnswer" : {"_value" : "2018-03-05", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2018-03-05T16:19:20.52Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2018-02-23", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Mast Cell Activation Syndrome"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if his Department will include Mast Cell Activation Syndrome (MCAS) in the 100K genome project and establish links to the MCAS Research Centre at the University of Bonn Institute of Genetics.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/18", "label" : {"_value" : "Biography information for Dame Cheryl Gillan"}
}
, "tablingMemberConstituency" : {"_value" : "Chesham and Amersham"}
, "tablingMemberPrinted" : [{"_value" : "Dame Cheryl Gillan"}
], "uin" : "129388"}
, {"_about" : "http://data.parliament.uk/resources/847713", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/847713/answer", "answerText" : {"_value" : " NHS Digital publishes the number of vacancies that are advertised on NHS Jobs, the dedicated online recruitment service for the National Health Service. However, as the basis of the figures is the number of vacancies advertised for the first time in each given month, it is not possible to determine from these figures the number of vacancies live at any given point in time. The figures only cover those vacancies advertised via NHS Jobs, and it is not always possible to determine how many posts are associated with any given advertisement. The published figures are at the Health Education England region and do not go to the level of individual trusts.<\/p> <\/p> This data is relatively new and there is limited data to establish trends. It is also important to note the distinction between job adverts and actual vacancies as many trusts are in a constant process of recruitment with single job adverts often covering multiple job vacancies.<\/p> <\/p> The latest NHS Digital figures show that over 34,000 nursing and midwifery vacancies were advertised in the three months to September 2017 across England.<\/p> <\/p> The NHS Digital vacancy figures are available at the following link:<\/p> <\/p>